9-33264264-C-A
Position:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_001349299.2(BAG1):c.-4G>T variant causes a 5 prime UTR premature start codon gain change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000167 in 1,613,306 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000099 ( 0 hom., cov: 31)
Exomes 𝑓: 0.0000082 ( 0 hom. )
Consequence
BAG1
NM_001349299.2 5_prime_UTR_premature_start_codon_gain
NM_001349299.2 5_prime_UTR_premature_start_codon_gain
Scores
2
17
Clinical Significance
Conservation
PhyloP100: 0.0370
Genes affected
BAG1 (HGNC:937): (BAG cochaperone 1) The oncogene BCL2 is a membrane protein that blocks a step in a pathway leading to apoptosis or programmed cell death. The protein encoded by this gene binds to BCL2 and is referred to as BCL2-associated athanogene. It enhances the anti-apoptotic effects of BCL2 and represents a link between growth factor receptors and anti-apoptotic mechanisms. Multiple protein isoforms are encoded by this mRNA through the use of a non-AUG (CUG) initiation codon, and three alternative downstream AUG initiation codons. A related pseudogene has been defined on chromosome X. [provided by RefSeq, Feb 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.057750165).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BAG1 | NM_004323.6 | c.411G>T | p.Glu137Asp | missense_variant | 1/7 | ENST00000634734.3 | NP_004314.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BAG1 | ENST00000634734.3 | c.411G>T | p.Glu137Asp | missense_variant | 1/7 | 1 | NM_004323.6 | ENSP00000489189.2 |
Frequencies
GnomAD3 genomes AF: 0.0000986 AC: 15AN: 152136Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
15
AN:
152136
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000281 AC: 7AN: 249394Hom.: 0 AF XY: 0.0000371 AC XY: 5AN XY: 134952
GnomAD3 exomes
AF:
AC:
7
AN:
249394
Hom.:
AF XY:
AC XY:
5
AN XY:
134952
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000821 AC: 12AN: 1461170Hom.: 0 Cov.: 30 AF XY: 0.00000825 AC XY: 6AN XY: 726878
GnomAD4 exome
AF:
AC:
12
AN:
1461170
Hom.:
Cov.:
30
AF XY:
AC XY:
6
AN XY:
726878
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000986 AC: 15AN: 152136Hom.: 0 Cov.: 31 AF XY: 0.0000942 AC XY: 7AN XY: 74334
GnomAD4 genome
AF:
AC:
15
AN:
152136
Hom.:
Cov.:
31
AF XY:
AC XY:
7
AN XY:
74334
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
2
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 27, 2023 | The c.411G>T (p.E137D) alteration is located in exon 1 (coding exon 1) of the BAG1 gene. This alteration results from a G to T substitution at nucleotide position 411, causing the glutamic acid (E) at amino acid position 137 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
.;.;T;T;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;T;T;T;T
M_CAP
Benign
T
MetaRNN
Benign
T;T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
.;.;M;.;.
PrimateAI
Benign
T
PROVEAN
Benign
.;N;.;N;.
REVEL
Benign
Sift
Benign
.;T;.;D;.
Sift4G
Benign
T;T;.;.;T
Polyphen
0.31
.;.;B;.;.
Vest4
MutPred
Loss of helix (P = 0.0558);.;Loss of helix (P = 0.0558);.;.;
MVP
0.46
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at